Clearside Biomedical, Inc. (CLSD) Covered Calls

You can sell covered calls on Clearside Biomedical, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CLSD (prices last updated Fri 4:16 PM ET):

Clearside Biomedical, Inc. (CLSD) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
1.31 -0.01 1.25 1.37 227K - 0.1
Covered Calls For Clearside Biomedical, Inc. (CLSD)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
May 17 2.5 0.00 1.37 0.0% 0.0%
Jun 21 2.5 0.00 1.37 0.0% 0.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema. The company also engages in the development of therapies in various areas, such as gene therapy for inherited retinal disorders, neovascular age-related macular degeneration, and other ocular diseases. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.